SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Azitra, Inc. AZTR NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Azitra, Inc. (AZTR) is a Biotechnology company in the Healthcare sector, currently trading at $0.22. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 2 out of 7 criteria passed.

Valuation: AZTR trades at a trailing Price-to-Earnings (P/E) of -0.1 (S&P 500 average ~25).

Net income is $11M (loss), growing at -2.4%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+142.9 pp trend).

Balance sheet: total debt is $422M against $3.8B equity (Debt-to-Equity (D/E) ratio 0.11, conservative). Current ratio is 2.83 (strong liquidity). Debt-to-assets is 8.4%. Total assets: $5.0B.

Analyst outlook: 1 / 1 analysts rate AZTR as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 100/100 (Pass), Income ?/100 (Fail).

AZTR SharesGrow Score Overview

75/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 50/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AZTR

AZTR trades at a trailing Price-to-Earnings (P/E) of -0.1 (S&P 500 average ~25). Trailing PEG 0.01. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

AZTR: +344.9%/yr revenue is, -2.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet AZTR: Debt-to-Equity (D/E) ratio 0.11 (conservative), Current ratio is 2.83 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

AZTR: Gross margin is 100% (+142.9 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 1 analysts rate AZTR as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range0.1-2.66667

Volume411.73K

Avg Volume (30D)12.83M

Market Cap$2.36M

Beta (1Y)-2.18

Share Statistics

EPS (TTM)-2.25

Shares Outstanding$4.87M

IPO Date2023-06-20

Employees12

CEOFrancisco D. Salva

Financial Highlights & Ratios

Gross Profit$-453.14K

EBITDA$-10.49M

Net Income$-10.96M

Operating Income$-10.97M

Total Cash$2.07B

Total Debt$422.08M

Net Debt$-1.65B

Total Assets$5.03B

Price / Earnings (P/E)-0.1

Analyst Forecast

Rating ConsensusBuy

Analysts Covering1

Buy 100% Hold 0% Sell 0%

Company Info

CountryUS

ExchangeNYSE

CurrencyUSD

ISINUS05479L3024

Price Chart

AZTR

Azitra, Inc. ↗ · NYSE

Healthcare • Biotechnology

0.10 52WK RANGE 2.67

People Also View

Jasper Therapeutics, Inc.

Salarius Pharmaceuticals, Inc.

Indaptus Therapeutics, Inc.

Revelation Biosciences, Inc.

Onconetix, Inc.

Enveric Biosciences, Inc.

Scinai Immunotherapeutics Ltd.

Silexion Therapeutics Ltd.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message